NovoCure Limited (NVCR) Stock Price & How to Invest

NovoCure Ltd. (Nasdaq: NVCR) is an oncology medical device company built around Tumor Treating Fields (TTFields), a therapy that delivers low-intensity alternating electric fields through wearable arrays to disrupt cancer cell division. Its FDA-approved Optune platform spans Optune Gio for glioblastoma, Optune Lua for metastatic non-small cell lung cancer and malignant pleural mesothelioma, and Optune Pax, approved in February 2026 for locally advanced pancreatic cancer. Optune Pax has since launched in Germany under a CE mark and on October 1, 2026 received approval in Japan for unresectable locally advanced pancreatic cancer. The company reported full-year 2025 net revenue of about $655 million (up ~8%) with roughly 4,620 active patients on therapy at year-end. Frank Leonard became chief executive in late 2025.

The investment picture is a growth-versus-profitability tension. The core glioblastoma business is mature and slower-growing (Optune Gio volume grew about 8% in the first half of 2026), so the equity story now hinges on newer indications (lung and pancreatic) and international expansion driving the next leg. Revenue reached about $184 million in Q2 2026, up about 16% year over year, and analysts expect about $726 million for the full year, above the $690 million to $710 million range management gave early in 2026. The company still posts GAAP net losses: a $71.1 million loss in Q1 2026, inflated by a one-time share-based-comp charge tied to the Optune Pax approval, then a much smaller $15.7 million loss in Q2. Gross margins in the high 70s and cash of about $441 million give runway, but the path to sustained profitability depends heavily on adoption of the new launches and clinical readouts in additional tumor types.

NovoCure remains GAAP unprofitable (a trailing net loss of about $149 million) and depends on new launches converting into durable revenue, which is not guaranteed. Its Phase 3 TRIDENT trial in newly diagnosed glioblastoma failed to meet its primary overall-survival endpoint, a reminder that clinical bets can disappoint and that the mature glioblastoma base offers limited upside. Reimbursement decisions, physician adoption of an unfamiliar device modality, and competition from drug-based oncology standards of care all create uncertainty. In September 2026 the company disclosed a cybersecurity incident that exposed patient data, which adds regulatory and reputational risk. The stock has been volatile, falling about 16% in the month to October 16, 2026 and sitting far below its historical highs, and heavy reliance on a single technology platform concentrates risk. Currency swings that recently helped revenue can also reverse.

7 analysts publish price targets on NVCR, averaging $26.86 against a $14.07 price as of October 2026, or +90.9%. The published targets run from $17.00 to $52.00, a wide spread, and the ratings split 4 buy, 3 hold, 0 sell. Over the last six months there have been 4 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NVCR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on NovoCure Limited. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. New-indication launches (Optune Pax and Lua). The February 2026 U.S. The most optimistic published target, $52.00, assumes this works close to its best case.

The case against. NovoCure remains GAAP unprofitable (a trailing net loss of about $149 million) and depends on new launches converting into durable revenue, which is not guaranteed. The most pessimistic target, $17.00, is roughly what NVCR is worth if this bites instead.

Read the full bull and bear case on NVCR, including what would have to change to break either one. Walnut is not an investment adviser.

No. NovoCure Limited (NVCR) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see NovoCure Limited's investor relations page or your broker.

• Revenue (TTM): ~$699M
• Revenue (Q2 2026): ~$184M (up ~16% YoY)
• Revenue (2026 consensus): ~$726M
• Gross margin (TTM): ~76%
• Net loss (TTM): ~$149M (~$1.30/share)
• Cash / debt: ~$441M / ~$233M (Jun 30, 2026)
• Market cap: ~$1.6B

NovoCure trades at about 2.3 times trailing sales as a mid-teens-growth medical device company that is still not GAAP profitable, so it is valued more on revenue and future-indication optionality than on earnings. The Q1 2026 loss was amplified by a roughly $43 million one-time share-based-comp charge linked to the Optune Pax approval, while Q2 narrowed to about $16 million. About $441 million in cash against about $233 million of debt gives operating runway while the newer launches scale; Q3 2026 results are due October 29, with consensus EPS of about -$0.23.

Other names that sit close to NVCR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get NVCR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NVCR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NVCR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

NovoCure is a revenue-generating, still-unprofitable oncology device play where the thesis rides on new-indication launches offsetting a mature glioblastoma base. Q2 2026 brought its smallest loss in a year and management is aiming for at least adjusted EBITDA break-even by year-end 2026, which makes the October 29 Q3 report a check on that path.

Whether NVCR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NVCR a buy or a sell?, and where the stock could go from here in the NVCR stock forecast.

For income investors, whether NVCR pays a dividend and how the payout looks is covered in does NVCR pay a dividend? And to weigh NVCR against a peer, read the full side-by-side comparisons: NVCR vs BMY and NVCR vs BSX.